ME02659B - Antitelo mat3 koje neutrauše prolaktinski receptor i njegova terapeutska primena - Google Patents
Antitelo mat3 koje neutrauše prolaktinski receptor i njegova terapeutska primenaInfo
- Publication number
- ME02659B ME02659B MEP-2016-91A MEP201691A ME02659B ME 02659 B ME02659 B ME 02659B ME P201691 A MEP201691 A ME P201691A ME 02659 B ME02659 B ME 02659B
- Authority
- ME
- Montenegro
- Prior art keywords
- antigen
- antibody
- binding fragment
- cell
- seq
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (22)
1.Antitelo Mat3 ili njegov fragment koji veže antigen, naznačeno time, što antagonizuje signaliziranje koje je posredovano prolaktinskim receptorom, pri čemu pomenuto antitelo ili njegov fragment koji veže antigen obuhvataa.varijabilni teški region sa amino-kiselinskom sekvencom u skladu sa SEQ ID Br: 1; ib.varijabilni laki region sa amino-kiselinskom sekvencom u skladu sa SEQ ID Br: 2.
2.Antitelo ili njegov fragment koji veže antigen u skladu sa zahtevom 1, naznačeno time, što se pomenuti sastoje od regiona koji veće antigen koji može da se specifično veže na jedan ili više regiona iz izvan-ćelijskog domena prolaktinskog receptora (PRLR) od ljudi, majmuna i miševa, i pri čemu su amino-kiselinske sekvence ljudskog PRLR predstavljene sa amino-kiselinskim sekvencama od pozicije 1 do 210 u SEQ ID Br: 12 i ljudskim polimorfnim varijantama iz SEQ ID Br: 12, sa amino-kiselinskim sekvencama od pozicije 1 do 210 iz majmunskog PRLR u skladu sa SEQ ID Br: 11 i iz mišjeg PRLR u skladu sa SEQ ID Br: 13.
3.Antitelo ili njegov fragment koji veže antigen u skladu sa zahtevom 2, naznačeno time, što afinitet prema izvan-ćelijskim domenom u PRLR od ljudi, majmuna i miševa iznosi 100 nM, manje od 30 nM, ili svega 10 nM, i pri čemu je pomenuti afinitet izmeren primenom površinske plazmon rezonance, na primer Biacore.
4.Antitelo ili njegov fragment koji veže antigen u skladu sa zahtevom 1, naznačeno time, što se sastoji od regiona koji veže antigen koji može da se veže specifično na jedan ili više regiona iz izvan-ćelijskog domena iz ljudskog PRLR i gde afinitet iznosi 10 nM ili 1 nM, a pri čemu je pomenuti afinitet izmeren primenom površinske plazmon rezonance, na primer Biacore.
5.Antitelo ili njegov fragment koji veže antigen u skladu sa bilo kojim od zahteva od 1 do 4, naznačeno time, što su konstantni domeni iz teškog lanca modifikovani ili nemodifikovani IgG1, IgG2, IgG3 ili IgG4.
6.Izolovana sekvenca nukleinske kiseline, naznačena time, što kodira antitelo ili fragment koji veže antigen u sladu sa bilo kojim od zahteva od 1 do 5.
7.Izolovana sekvenca nukleinske kiseline u skladu sa zahtevom 6, naznačena time, što je to sekvenca u skladu sa SEQ ID Br: 3 i 4.
8.Ekspresioni vektor, naznačen time, što sadrži sekvencu nukleinske kiseline iz zahteva 6 ili 7.
9.Ćelija domaćin, naznačena time, što sadrži vektor iz zahteva 8 ili molekul nukleinske kiseline iz zahteva 6 ili 7, pri čemu pomenuta ćelija domaćin je ćelija višeg eukariota, ćelija nižeg eukariota, ili ćelija prokariota.
10.Ćelija domaćin iz zahteva 9, naznačena time, što ćelija višeg eukariota je ćelija nekog sisara.
11.Ćelija domaćin iz zahteva 9, naznačena time, što ćelija nižeg eukariota je ćelija kvasca.
12.Ćelija domaćin iz zahteva 9, naznačena time, što ćelija prokariota je ćelija bakterije.
13.Postupak primene ćelija domaćina iz zahteva 9 do 12, naznačen time, što omogućava proizvodnju antitela ili fragmenta koji veže antigen, a obuhvata kultiviranje ćelija domaćina iz zahteva 9 u pogodnim uslovima i obnavljanje pomenutog antitela.
14.Antitelo ili fragment koji veže antigen, naznačeno time, što je proizvedeno primenom postupka iz zahteva 13.
15.Antitelo ili fragment koji veže antigen iz bilo kojeg od zahteva od 1 do 5, naznačeno time, što je prečišćeno do težinske homogenosti od najmanje 95%.
16.Antitelo ili fragment koji veže antigen u skladu sa bilo kojim od zahteva od 1 do 5, naznačeno time, što se upotrebljava kao lek.
17.Farmaceutska kompozicija, naznačena time, što sadrži antitelo ili fragment koji veže antigen u skladu sa bilo kojim od zahteva od 1 do 5 i neki farmaceutski prihvatljivi nosilac obuhvatajući i ekscipijente i pomoćne materije.
18.Komplet hemikalija koji sadrži antitelo iz zahteva 1 do 5, naznačen time, što sadrži terapeutski efektivnu količinu antitela Mat3, spakovanog u kontejner, pri čemu pomenuti komplet hemikalija ponekad sadrži neki drugi terapeutski agens, i dodatno sadrži etiketu koja je zalepljena ili spakovana zajedno sa kontejnerom, pri čemu etiketa opisuje sadržaj kontejnera i navodi indikacije i/ili obezbeđuje instrukcije za upotrebu sadržaja kontejnera sa ciljem tretiranja endometrioze, adenomioze, benigne bolesti dojke i mastalgije, inhibicije laktacije, hiper- i normoprolaktinemski gubitak kose, benignu hiperplaziju prostate, fibroide ili sa ciljem primene kod ne-hormonalne ženske kontracepcije ili za tretman žena koje primaju kombinovanu hormonsku terapiju, terapiju estrogen plus progestin, za inhibiranje proliferacije ćelija iz epitela mlečnih žlezda ili za tretman i prevenciju raka dojke koji je rezistentan na antiestrogen.
19.Antitelo ili fragment koji veže antigen u skladu sa bilo kojim od zahteva od 1 do 5, naznačeno time, što se upotrebljava u nekom leku za tretiranje i/ili prevenciju endometrioze i adenomioze, endometriosis interna.
20.Antitelo ili fragment koji veže antigen u skladu sa bilo kojim od zahteva od 1 do 5, naznačeno time, što se upotrebljava u nekom leku za tretman benigne bolesti dojke i mastalgije.
21.Antitelo ili fragment koji veže antigen u skladu sa bilo kojim od zahteva od 1 do 5, naznačeno time, što se upotrebljava u nekom leku za tretman ili prevenciju raka dojke koji je rezistentan na antiestrogen.
22.Farmaceutska kompozicija u skladu sa zahtevom 17, naznačena time, što sadrži antitela ili fragment koji veže antigen protiv PRLR iz bilo kojeg od zahteva od 1 do 5, u kombinaciji sa najmanje jednim dodatnim agensom.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11168644A EP2530089A1 (en) | 2011-06-03 | 2011-06-03 | Neutralising prolactin receptor antibody Mat3 and its therapeutical use |
| PCT/EP2012/060078 WO2012163932A1 (en) | 2011-06-03 | 2012-05-31 | Neutralizing prolactin receptor antibody mat3 and its therapeutic use |
| EP12729030.2A EP2714740B1 (en) | 2011-06-03 | 2012-05-31 | Neutralizing prolactin receptor antibody mat3 and its therapeutic use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02659B true ME02659B (me) | 2017-06-20 |
Family
ID=46331236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2016-91A ME02659B (me) | 2011-06-03 | 2012-05-31 | Antitelo mat3 koje neutrauše prolaktinski receptor i njegova terapeutska primena |
Country Status (37)
| Country | Link |
|---|---|
| US (2) | US9353186B2 (me) |
| EP (2) | EP2530089A1 (me) |
| JP (1) | JP5859641B2 (me) |
| KR (1) | KR101920521B1 (me) |
| CN (1) | CN103764679B (me) |
| AP (1) | AP2013007266A0 (me) |
| AR (1) | AR086631A1 (me) |
| AU (1) | AU2012264765B2 (me) |
| BR (1) | BR112013030995B1 (me) |
| CA (1) | CA2837736C (me) |
| CL (1) | CL2013003459A1 (me) |
| CO (1) | CO6852025A2 (me) |
| CR (1) | CR20130632A (me) |
| CU (1) | CU20130163A7 (me) |
| CY (1) | CY1117660T1 (me) |
| DK (1) | DK2714740T3 (me) |
| DO (1) | DOP2013000285A (me) |
| EA (1) | EA029316B1 (me) |
| EC (1) | ECSP13013063A (me) |
| ES (1) | ES2572215T3 (me) |
| HR (1) | HRP20160506T1 (me) |
| HU (1) | HUE028775T2 (me) |
| IL (1) | IL229504B (me) |
| MA (1) | MA35237B1 (me) |
| ME (1) | ME02659B (me) |
| MX (1) | MX343683B (me) |
| PE (1) | PE20141158A1 (me) |
| PH (1) | PH12013502494A1 (me) |
| PL (1) | PL2714740T3 (me) |
| RS (1) | RS54727B1 (me) |
| SG (1) | SG195060A1 (me) |
| SI (1) | SI2714740T1 (me) |
| TN (1) | TN2013000501A1 (me) |
| TW (1) | TWI548649B (me) |
| UY (1) | UY34116A (me) |
| WO (1) | WO2012163932A1 (me) |
| ZA (1) | ZA201309683B (me) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ631565A (en) | 2012-03-14 | 2016-07-29 | Regeneron Pharma | Multispecific antigen-binding molecules and uses thereof |
| EP2935331B1 (en) | 2012-12-24 | 2018-02-28 | AbbVie Inc. | Prolactin receptor binding proteins and uses thereof |
| US9545451B2 (en) | 2013-08-21 | 2017-01-17 | Regeneron Pharmaceuticals, Inc. | Anti-PRLR antibodies and methods for killing PRLR-expressing cells |
| TWI641620B (zh) | 2013-08-21 | 2018-11-21 | 再生元醫藥公司 | 抗－ｐｒｌｒ抗體及其用途 |
| MY189159A (en) | 2015-07-06 | 2022-01-29 | Regeneron Pharma | Multispecific antigen-binding molecules and uses thereof |
| WO2017190079A1 (en) | 2016-04-28 | 2017-11-02 | Regeneron Pharmaceuticals, Inc. | Methods of making multispecific antigen-binding molecules |
| EP3548514A1 (en) | 2016-11-29 | 2019-10-09 | Regeneron Pharmaceuticals, Inc. | Methods of treating prlr positive breast cancer |
| TW201836647A (zh) | 2017-04-06 | 2018-10-16 | 美商艾伯維有限公司 | 抗－ｐｒｌｒ抗體藥物軛合物（ａｄｃ）及其用途 |
| AU2018300687A1 (en) | 2017-07-10 | 2019-12-19 | Bayer Pharma Aktiengesellschaft | Prolactin receptor antibody for male and female pattern hair loss |
| PT3587445T (pt) * | 2017-08-10 | 2024-03-14 | Grifols Diagnostic Solutions Inc | Um marcador de oligomerização compreendendo uma região fc de imunoglobulina e um domínio poli-his |
| CN112040985A (zh) | 2018-02-07 | 2020-12-04 | 瑞泽恩制药公司 | 用于递送治疗性蛋白质的方法和组合物 |
| AR124681A1 (es) | 2021-01-20 | 2023-04-26 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
| EP4428150A1 (en) | 2023-03-07 | 2024-09-11 | Peptide Logic LLC | Antibody or antigen-binding fragment thereof |
| CN116655791B (zh) * | 2023-05-06 | 2023-11-07 | 浙江触奇生物科技有限公司 | 一种抗泌乳素受体的纳米抗体、重组载体、重组菌和应用 |
| CN120388750B (zh) * | 2025-04-15 | 2025-12-09 | 绵阳市妇幼保健院(绵阳市儿童医院) | 一种子宫内膜异位症患者哺乳期复查随访数据处理系统 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
| JP4157160B2 (ja) | 1991-12-13 | 2008-09-24 | ゾーマ テクノロジー リミテッド | 改変抗体可変領域の調製のための方法 |
| ATE219517T1 (de) | 1995-08-18 | 2002-07-15 | Morphosys Ag | Protein-/(poly)peptidbibliotheken |
| GB9701425D0 (en) | 1997-01-24 | 1997-03-12 | Bioinvent Int Ab | A method for in vitro molecular evolution of protein function |
| WO2003008583A2 (en) | 2001-03-02 | 2003-01-30 | Sagres Discovery | Novel compositions and methods for cancer |
| AU2002322280A1 (en) | 2001-06-21 | 2003-01-21 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
| EP1325930A1 (en) * | 2002-01-08 | 2003-07-09 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Mammal prolactin variants |
| EP2083088A3 (en) | 2005-04-07 | 2009-10-14 | Novartis Vaccines and Diagnostics, Inc. | Cancer-related genes |
| US7422899B2 (en) | 2005-10-05 | 2008-09-09 | Biogen Idec Ma Inc. | Antibodies to the human prolactin receptor |
| EP3018144A1 (en) * | 2006-08-18 | 2016-05-11 | XOMA Technology Ltd. | Prlr-specific antibody and uses thereof |
| EP2332995A1 (en) * | 2009-12-10 | 2011-06-15 | Bayer Schering Pharma Aktiengesellschaft | Neutralizing prolactin receptor antibodies and their therapeutic use |
-
2011
- 2011-06-03 EP EP11168644A patent/EP2530089A1/en not_active Withdrawn
-
2012
- 2012-05-31 SI SI201230553A patent/SI2714740T1/sl unknown
- 2012-05-31 KR KR1020137034848A patent/KR101920521B1/ko active Active
- 2012-05-31 HU HUE12729030A patent/HUE028775T2/en unknown
- 2012-05-31 DK DK12729030.2T patent/DK2714740T3/da active
- 2012-05-31 MX MX2013014174A patent/MX343683B/es active IP Right Grant
- 2012-05-31 RS RS20160322A patent/RS54727B1/sr unknown
- 2012-05-31 CN CN201280038107.4A patent/CN103764679B/zh active Active
- 2012-05-31 PE PE2013002749A patent/PE20141158A1/es active IP Right Grant
- 2012-05-31 AP AP2013007266A patent/AP2013007266A0/xx unknown
- 2012-05-31 PL PL12729030T patent/PL2714740T3/pl unknown
- 2012-05-31 CA CA2837736A patent/CA2837736C/en active Active
- 2012-05-31 BR BR112013030995-4A patent/BR112013030995B1/pt active IP Right Grant
- 2012-05-31 JP JP2014513160A patent/JP5859641B2/ja active Active
- 2012-05-31 ME MEP-2016-91A patent/ME02659B/me unknown
- 2012-05-31 WO PCT/EP2012/060078 patent/WO2012163932A1/en not_active Ceased
- 2012-05-31 PH PH1/2013/502494A patent/PH12013502494A1/en unknown
- 2012-05-31 ES ES12729030T patent/ES2572215T3/es active Active
- 2012-05-31 EP EP12729030.2A patent/EP2714740B1/en active Active
- 2012-05-31 AU AU2012264765A patent/AU2012264765B2/en active Active
- 2012-05-31 HR HRP20160506TT patent/HRP20160506T1/hr unknown
- 2012-05-31 US US14/123,517 patent/US9353186B2/en active Active
- 2012-05-31 SG SG2013085816A patent/SG195060A1/en unknown
- 2012-05-31 EA EA201301356A patent/EA029316B1/ru not_active IP Right Cessation
- 2012-06-01 AR ARP120101933A patent/AR086631A1/es active IP Right Grant
- 2012-06-01 TW TW101119849A patent/TWI548649B/zh active
- 2012-06-01 UY UY0001034116A patent/UY34116A/es not_active Application Discontinuation
-
2013
- 2013-11-19 IL IL229504A patent/IL229504B/en active IP Right Grant
- 2013-12-02 MA MA36513A patent/MA35237B1/fr unknown
- 2013-12-02 TN TNP2013000501A patent/TN2013000501A1/fr unknown
- 2013-12-03 CL CL2013003459A patent/CL2013003459A1/es unknown
- 2013-12-03 CO CO13283823A patent/CO6852025A2/es not_active Application Discontinuation
- 2013-12-03 CR CR20130632A patent/CR20130632A/es unknown
- 2013-12-03 DO DO2013000285A patent/DOP2013000285A/es unknown
- 2013-12-03 CU CU2013000163A patent/CU20130163A7/es unknown
- 2013-12-03 EC ECSP13013063 patent/ECSP13013063A/es unknown
- 2013-12-20 ZA ZA2013/09683A patent/ZA201309683B/en unknown
-
2016
- 2016-04-28 US US15/140,629 patent/US9777063B2/en active Active
- 2016-06-17 CY CY20161100549T patent/CY1117660T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20160506T1 (hr) | Neutralizirajuće prolaktin receptorsko protutijelo mat3 i njegova terapijska uporaba | |
| US11999789B2 (en) | Humanized antibodies to TNF-like ligand 1A (TL1A) and uses thereof | |
| TWI871367B (zh) | 針對類-tnf配體1a(tl1a)之人類化抗體及其用途 | |
| US12558420B2 (en) | Methods for treating inflammation using antibodies to kallidin and des-Arg10-kallidin | |
| US10391155B2 (en) | Peptidic chimeric antigen receptor T cell switches and uses thereof | |
| HRP20170016T1 (hr) | Neutralizirajuća antitijela prolaktin receptora i njihova terapeutska uporaba | |
| CN113316590A (zh) | 抗nkg2a抗体及其用途 | |
| EP3529268A1 (en) | Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof | |
| JP2024508762A (ja) | 抗ｔｌ１ａ抗体組成物及び肺における治療方法 | |
| JP2024506940A (ja) | Ｔｎｆ様リガンド１ａ（ｔｌ１ａ）に対するヒト化抗体を含む組成物及びその使用 | |
| CN116640214A (zh) | 分离抗体及其应用 | |
| TW202313683A (zh) | 抗nkg2a抗體及組合物 | |
| Li et al. | Monoclonal antibody against EV71 3Dpol inhibits the polymerase activity of RdRp and virus replication | |
| CN120917045A (zh) | 治疗皮肤的抗tl1a抗体组合物和方法 | |
| WO2024021839A1 (zh) | 一种稳定性提高的人源化单克隆抗体及其应用 | |
| AU2022246842A1 (en) | Multispecific binding moieties comprising novel pd-1 binding domains | |
| CN118557719A (zh) | GHR-106单克隆抗体作为GnRH拮抗剂的用途 | |
| TW202228768A (zh) | 用於治療疼痛之化合物及方法 | |
| CN119256009A (zh) | 与人dr3特异性结合的抗体及其用途 | |
| CN117202932A (zh) | 治疗肺部的抗tl1a抗体组合物和方法 | |
| CN117222429A (zh) | 包括针对tnf样配体1a（tl1a）的人源化抗体的组合物以及其用途 |